Case Link: Novartis AG & Anr. vs Cipla Ltd.
Citation
2015 SCC OnLine Del 6589
Court
Delhi High Court
Judge
Justice Manmohan Singh
Date of Judgment
9 January 2015
Relevant Law
- Patents Act, 1970
- Section 48 – Rights of Patentee
- Section 64 – Revocation of Patents
- Section 83 – General Principles Applicable to Working of Patents
- Section 84 – Compulsory Licensing
- Section 92 – Special Provision for Compulsory Licences
- Section 108 – Relief in Patent Infringement Suits
- Order XXXIX Rules 1 and 2 of the Code of Civil Procedure, 1908
Facts of the Case
Novartis AG, a Swiss pharmaceutical company, was the proprietor of Indian Patent No. 222346 relating to the compound Indacaterol, a drug used for the treatment of Chronic Obstructive Pulmonary Disease (COPD). The drug was marketed globally and in India under the brand name ONBREZ. Novartis claimed that Indacaterol represented an innovative pharmaceutical invention developed after extensive research and substantial financial investment. The patented drug was being imported into India and distributed through its Indian affiliates and business partners.
Cipla Ltd., one of India’s leading pharmaceutical companies, launched a generic version containing Indacaterol and began commercial activities relating to the product. Novartis alleged that Cipla’s product infringed its patent rights and therefore filed a suit seeking a permanent injunction, damages, and other reliefs.
Prior to the suit, Cipla had approached governmental authorities under Sections 66 and 92 of the Patents Act seeking revocation of the patent and intervention on public interest grounds. Cipla argued that COPD constituted a major public health concern and that Novartis was not adequately making the patented drug available in India because it was importing limited quantities rather than manufacturing the product domestically.
The dispute came before the Delhi High Court primarily on Novartis’ application for an interim injunction restraining Cipla from manufacturing and selling the allegedly infringing product pending disposal of the suit.
Issues Before the Court
The Court considered the following issues:
- Whether Novartis had established a prima facie case of patent infringement.
- Whether the suit patent appeared valid and enforceable.
- Whether Cipla had raised a credible challenge to the validity of the patent.
- Whether alleged non-working of the patent in India could be used as a defence in an infringement action.
- Whether public interest considerations relating to access to medicines justified refusal of an interim injunction.
- Whether Novartis was entitled to interim protection under Sections 48 and 108 of the Patents Act.
Arguments of Novartis
Novartis argued that Patent No. 222346 was a valid and subsisting patent that had not been successfully challenged through pre-grant or post-grant opposition proceedings. According to Novartis, the patent conferred exclusive statutory rights under Section 48 of the Patents Act, including the right to prevent unauthorized manufacture, use, sale, or distribution of the patented invention.
The plaintiffs contended that Cipla had deliberately launched an infringing product despite being fully aware of the existence of the patent. They argued that Cipla had failed to establish any credible ground for invalidity and that merely citing prior art documents without detailed technical explanation was insufficient to challenge patent validity.
Novartis further argued that issues relating to compulsory licensing, affordability, and public health fell within the jurisdiction of statutory authorities under Chapter XVI of the Patents Act and could not be imported as defences into a patent infringement suit.
Arguments of Cipla
Cipla challenged the grant of interim relief on several grounds.
First, it questioned the validity of the patent and argued that Novartis had not established a strong prima facie case. Second, Cipla contended that Novartis was not “working” the patent in India because the product was merely being imported rather than manufactured domestically. According to Cipla, the Patents Act encourages local working of inventions and discourages monopolies based solely on importation.
Cipla also invoked public interest considerations. It argued that COPD affected a large number of patients and that broader access to affordable medicines should weigh against the grant of an injunction. Cipla claimed that restricting generic competition would adversely affect patients requiring treatment.
The defendant further submitted that Sections 83 and 84 of the Patents Act reflected legislative concern regarding accessibility and affordability of patented products and that these principles should influence the Court’s exercise of discretion while considering interim relief.
Judgment
The Delhi High Court granted an interim injunction in favour of Novartis and restrained Cipla from manufacturing and selling the allegedly infringing product during the pendency of the suit.
The Court held that Novartis had established a strong prima facie case. It observed that the patent had remained unchallenged for several years and that Cipla had not produced sufficient material to demonstrate a credible challenge to validity. Mere references to prior art documents without technical analysis were insufficient to displace the presumption favouring the patent holder at the interlocutory stage.
The Court rejected Cipla’s argument that non-working of the patent in India could serve as a defence in an infringement suit. It held that questions concerning compulsory licensing, local working, public requirements, and affordability fall within Chapter XVI of the Patents Act and are to be considered by the Controller or other competent authorities. Such issues do not automatically defeat a patentee’s right to seek protection in infringement proceedings.
Justice Manmohan Singh emphasized that Sections 83 and 84 operate in a distinct statutory framework relating to compulsory licensing and revocation on grounds of non-working. The civil court hearing an infringement action cannot assume the role of the Controller and adjudicate matters specifically assigned to other statutory authorities.
The Court further held that public interest arguments must be supported by evidence. Cipla had not produced sufficient material demonstrating any actual shortage of the drug or failure by Novartis to meet market demand. Therefore, the balance of convenience favoured Novartis.
Accordingly, an interim injunction was granted restraining Cipla from dealing in the infringing product pending final adjudication of the dispute.
Legal Principles Established
1. Patent Rights Under Section 48 Are Enforceable Through Injunctions
A patentee possessing a valid and subsisting patent is entitled to seek injunctive relief against infringing activities.
2. Non-Working Defence Cannot Automatically Defeat Infringement Claims
Questions relating to local working, compulsory licensing, and public requirements are governed by separate provisions and cannot ordinarily be used as direct defences in infringement proceedings.
3. Public Interest Requires Evidentiary Support
General assertions regarding public health or affordability are insufficient unless supported by concrete evidence demonstrating actual public harm.
4. Distinction Between Infringement Jurisdiction and Compulsory Licensing Jurisdiction
The civil court deciding patent infringement cannot exercise powers specifically conferred upon the Controller or Central Government under Chapter XVI of the Patents Act.
5. Mere Assertion of Invalidity Is Insufficient
A defendant challenging patent validity must provide substantial material and technical explanation to establish a credible challenge.
Significance of the Case
The decision is important because it clarified the relationship between patent enforcement and public interest mechanisms under Indian patent law. The Court distinguished between infringement actions and compulsory licensing proceedings and held that statutory remedies designed to address affordability and accessibility concerns cannot automatically override patent rights in infringement suits.
The judgment also reinforced the principle that public interest arguments must be supported by evidence rather than broad policy assertions. It strengthened the position of patentees seeking interim protection while simultaneously preserving the separate statutory framework through which compulsory licences and public health interventions may be pursued.
The case is frequently cited in discussions concerning pharmaceutical patent enforcement, patent working requirements, and the balance between intellectual property rights and public access to medicines.
Conclusion
In Novartis AG v. Cipla Ltd., the Delhi High Court granted interim protection to the patent holder and held that allegations relating to non-working of patents, affordability, and public health concerns must ordinarily be addressed through the compulsory licensing framework rather than as direct defences in infringement proceedings. The Court emphasized the enforceability of patent rights under Section 48 while recognizing that public interest considerations are addressed through distinct statutory mechanisms under the Patents Act. The judgment remains a significant authority on pharmaceutical patent litigation and the interaction between patent monopolies and public health concerns in India.
Leave a Reply